Management
George Painter, Ph.D.
President and CEO
George Painter has twenty-four years of experience in the discovery and development of pharmaceutical agents, and most recently held the position of Executive Vice President, Research and Development, at Triangle Pharmaceuticals where he was a member of the founding management team. In addition to his management experience at Triangle Pharmaceuticals, Dr. Painter held positions at Burroughs Wellcome Co. beginning in 1983 including Director of Chemistry and Director of Virology. Subsequently, he served as Director of Research Process and International Deputy Therapeutic Head for Antiviral Research at Glaxo Wellcome Inc. Dr. Painter is a co-inventor of over forty-five patents, six of which have led to approved commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. He has led international teams, which generated data for nine investigational new drug applications and three new drug applications. Dr. Painter earned a B.S. in chemistry, an M.S. in physical organic chemistry and a Ph.D. in synthetic chemistry from Emory University.
Merrick Almond, Ph.D.
Vice President Research
Merrick Almond came to Chimerix most recently from Triangle Pharmaceuticals where he was Director, Chemistry. Dr. Almond was responsible for establishing a process exploration and optimization group that invented novel processes for five compounds under development at Triangle. Dr. Almond chaired Triangle's Patent Committee. Prior to Triangle, Dr. Almond spent 9 years in various research positions at Burroughs Wellcome, and held the position of Research Investigator at Glaxo Wellcome. During his time at Wellcome he was a recipient of the Wellcome Synthetic Organic Achievement Prize. Dr. Almond earned a B.S. in Biochemistry from the College of Environmental Science and Forestry in Syracuse, NY, and a Ph.D. in medicinal chemistry from Purdue University. He completed his postdoctoral research at Duke University. He has published 18 scientific papers, co-authored one review article, and is co-inventor of several patents.
Pamela Goss, CPA
Controller and Chief Accounting Officer
Pamela Goss joined Chimerix as Controller and Chief Accounting Officer in April 2005. Ms. Goss came to Chimerix from Gilead Sciences, Inc. where she was the Manager of Financial Planning and Analysis for the Durham, North Carolina site. At Gilead, she managed all financial functions at the Durham site and played an integral role in the successful integration after Gilead acquired Triangle Pharmaceuticals, Inc. in 2003. Previously, Ms. Goss was the Senior Associate Director of Finance for Triangle Pharmaceuticals, Inc., a publicly traded biotechnology company. Her most recent responsibilities at Triangle included financial reporting and strategic financial planning for mergers, acquisitions and alliances. She was a key contributor to the strategic alliance between Triangle and Abbott Laboratories serving as the finance liaison for the alliance. Ms. Goss is a Certified Public Accountant and earned a B.S. with high honors from North Carolina State University.
Neil Frazer, M.B., Ch.B., FRCA, FFPM
Chief Medical Officer
Prior to joining Chimerix, Dr. Frazer served as the Chief Medical Officer and Chief Operating Officer of Erimos Pharmaceuticals (previously Biocure Medical) where he was responsible for the design of clinical drug development programs to meet
Athanasios (Thanos) Maroglou Ph.D.
Vice President, Business Development
Thanos Maroglou has worked over 24 years as a senior executive with large and small life science companies. He was President and co-founder of Ercole Biotech Inc. a drug discovery company that developed splice switching drugs and was acquired by AVI BioPharma. Prior to this position he was an Associate with A.M. Pappas, a venture capital company. Dr Maroglou was VP of Project Management and an integral part of the executive team that took Paradigm Genetics Inc. public in 2000. Dr Maroglou spent the first 14 years of his career with E.I. DuPont DeNemours Inc. were he held positions of increasing management responsibility in research, manufacturing and business. Dr Maroglou earned a B.Sc. and Ph.D. in Chemical Engineering from the University of Birmingham, UK.
Rosemary O'Mahony, Ph.D.
Vice President Development
Rosemary O'Mahony has 19 years of experience in the development of pharmaceutical agents, and most recently held the position of Director, Chemical Development, at Triangle Pharmaceuticals. As the Director of Chemical Development Dr. O'Mahony was responsible for the large scale manufacture of bulk drug substance and was a key participant in the strategic alliance between Triangle and Abbott Laboratories. Dr. O'Mahony began her development career in the Chemical Development Group at Burroughs Wellcome and subsequently held several positions at Glaxo Wellcome including Team Manager, Chemical Development and Project Manager in the Worldwide Project Management Group. Dr. O'Mahony earned a B.S. in chemistry from Montclair State College and a Ph.D. in synthetic organic chemistry from the University of North Carolina at Chapel Hill.